Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: Implications for use of TSA in cancer therapy

Biochemical and Biophysical Research Communications

Volumn 302, Issue 2, 2003, Pages 181-185

  Ailenberg, Menachem ^a   Silverman, Mel ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; TRICHOSTATIN A;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL STRAIN 3T3; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; FIBROBLAST; FIBROSARCOMA; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0037428248     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00150-5     Document Type: Article

References (34)

1. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
2. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 64:1991;327-336.
3. Nagase H., Woessner J.F. Jr. Matrix metalloproteinases. J. Biol. Chem. 274:1999;21491-21494.
4. McCawley L.J., Martisian L.M. Matrix metalloproteinase: they're not just for matrix anymore. Curr. Opin. Cell Biol. 13:2001;534-540.
5. Westermarck J., Kahari V.-M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13:1999;781-792.
6. Vihinen P., Kahari V.-M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer. 99:2002;157-166.
7. Coussens L.M., Fingleton B., Martisian L.M. Cancer therapy: matrix metalloproteinases inhibitors and cancer-trials and tribulations. Science. 295:2002;2387-2392.
8. Yoshida M., Horinouchi S. Trichostatin and leptomycin inhibition of histone deacetylation and signal-dependent nuclear export. Ann. N.Y. Acad. Sci. 886:1999;23-35.
9. Cheung W.L., Briggsand S.D., Allis C.D. Acetylation and chromosomal function. Curr. Opin. Cell Biol. 12:2000;326-333.
10. Emerson B.M. Specificity of gene regulation. Cell. 109:2002;267-270.
11. Kuo M.-H., Allis C.D. Roles of histone acetyltransferases and deacetylases in gene regulation. BioEssays. 20:1998;615-626.
12. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Gen. Dev. 12:1998;599-606.
13. Kadonaga J.T., Grunstein M. Chromosomes and expression mechanisms chromatin: the packaging is the message. Curr. Opin. Gen. Dev. 9:1999;129-131.
14. Fry C.J., Peterson C.L. Chromatin remodeling enzymes: who's on first? Curr. Biol. 11:2001;R185-R197.
15. Rice J.C., Allis C.D. Code of silence. Nature. 414:2001;258-259.
16. Fry C.J., Peterson C.L. Unlocking the gates to gene expression. Science. 295:2002;1847-1848.
17. Narlikar G.J., Fan H.-Y., Kingston R.E. Cooperation between complexes that regulate chromatin structure and transcription. Cell. 108:2002;475-487.
18. Wolfe A.P., Hayes J.J. Chromatin disruption and modification. Nucleic acids Res. 27:1999;711-720.
19. Marks P.A., Richonand V.R., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:2000;1210-1216.
20. Berger S.L. Gene activation by histone and factor acetyltransferases. Curr. Opin. Cell Biol. 11:1999;336-341.
21. Archer S.Y., Hodin R.A. Histone acetylation and cancer. Curr. Opin. Gen. Dev. 9:1999;171-174.
22. D'Argenio G., Cosenza V., Cave M.D., Iovino P., Valle N.D., Lombardi G., Mazzacca G. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. Gastrointestinal. 110:1996;1727-1734.
23. Wu J.T., Archer S.Y., Hinnebusch B., Meng S., Hodin R.A. Transit vs. prolonged histone hyperacetylation: effect on colon cancer cell growth, differentiation, and apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 280:2001;G482-G490.
24. Van Lint C., Emiliani S., Verdin E. The expression of a small fraction of cellular gene is changed in response to histone deacetylation. Gene Expr. 5:1996;245-254.
25. Ailenberg M., Silverman M. Trichostatin A - histone deacetylase inhibitor with clinical therapeutic potential - is also a selective and potent inhibitor of gelatinase A expression. Biochem. Biophys. Res. Commun. 298:2002;110-115.
26. Mariadason J.M., Corner G.A., Augenlicht L.H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60:2000;4561-4572.
27. Ailenberg M., Weinstein T., Li I., Silverman M. Activation of procollagenase IV by cytochalasin D and concanavalin A in cultured rat mesangial cells: linkage to cytoskeletal reorganization. J. Am. Soc. Nephrol. 4:1994;1760-1770.
28. Ailenberg M., Silverman M. Cellular activation of mesangial gelatinase A by cytochalasin D is accompanied by enhanced mRNA expression by both gelatinase A and its membrane associated gelatinase A activator (MT-MMP). Biochem. J. 313:1996;879-884.
29. Ailenberg M., Silverman M. Cytochalasin D disruption of actin filaments in 3T3 cells produces an anti-apoptotic response by activating gelatinase A extracellularly and initiating intracellular survival signals. Biochim. Biophys. Acta. 1593:2003;249-258.
30. Van Wart H.E., Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA. 87:1990;5578-5582.
31. Lee H., Lee S., Baek M., Kim H.-Y., Jeoung D.-I. Expression profile analysis of trichostatin A in human gastric cancer cells. Biotech. Lett. 24:2002;377-381.
32. Medina V., Edmonds B., Young G.P., James R., Appleton S., Zalewski P.D. Induction of caspase 3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 57:1997;3697-3707.
33. Rechelhoff J.F., Tygart V.L., Mitias M.M., Walcott J.L. STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloprotease in rats. Diabetes. 42:1993;1425-1432.
34. Reuter A., Nestl A., Zwacka R.M., Tuckermann J., Waldherr R., Wagner E.-M., Hoyhtya M., Meyer zumm Gottesberge A.M., Angel P., Weiher H. Expression of recessive glomerulosclerosis gene Mvp17 regulates MMP-2 expression in fibroblasts, the kidney, and the inner ear of mice. Mol. Biol. Cell. 9:1998;1675-1682.